GlassScriptPhysician profile
Kyoko Sterns
NPI 1336813930
$2,086.21
in general payments reported to CMS, 2019-2025
20 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.28 · 2022: $50.25 · 2023: $817 · 2024: $743 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.57 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $407.78 | 2022-2025 | |
| Amgen INC. | $293.39 | 2022-2023 | Repatha |
| Scpharmaceuticals INC. | $190.23 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $140.92 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $96.16 | 2023 | Watchman Access System |
| Pfizer INC. | $86.81 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.95 | 2023-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $71.67 | 2024 | |
| Bridgebio Pharma, INC. | $49.74 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $48.42 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $29.91 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $25.58 | 2024 | Opsumit, Uptravi |
| Abiomed | $23.89 | 2025 | |
| Edwards Lifesciences Corporation | $19.75 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $19.27 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $18.89 | 2024 | |
| Genentech USA, INC. | $17.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2025 | |
| Esperion Therapeutics, INC. | $15.73 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyoko Sterns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.